Value of Information Methods for NHLBI Trials

NHLBI 试验的信息方法的价值

• 批准号: 9050702
• 负责人: ANIRBAN BASU
• 金额: $ 67.21万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-15 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9050702
• 关键词: Accounting; Acute; Area; Binding; Blood; Clinical; Clinical Trials; Communication; Computer software; Decision Making; Disease; Economics; Educational workshop; Expert Opinion; Face; Funding; Goals; Health; Heart; Heart Diseases; Hematological Disease; Imagery; Intervention; Investments; Knowledge; Literature; Lung; Lung diseases; Medical; Meta-Analysis; Methods; Modeling; National Heart, Lung, and Blood Institute; Online Systems; Outcome; Participant; Patient-Focused Outcomes; Plant Roots; Population; Process; Randomized Clinical Trials; Reporting; Research; Research Personnel; Risk; Sample Size; Science; Southwest Oncology Group; Testing; Time; Translating; Uncertainty; Work; base; cancer clinical trial; clinical decision-making; design; experience; improved; models and simulation; novel strategies; population health; prospective; systematic review; theories; tool; user-friendly

 DESCRIPTION (provided by applicant): NHLBI faces major challenges in determining how best to allocate investment in randomized clinical trials (RCTs). Currently, there is no consistent mechanism to evaluate and compare proposed RCTs for NHLBI to best determine where to invest its limited dollars. Novel approaches in decision science can provide valuable information to enhance the RCT prioritization process at NHLBI. The overall objective of this project is to develop a comprehensive toolkit of pragmatic value of information (VOI) approaches and the corresponding software that can be readily used by clinical researchers and funders in order to assess the value of RCTs related to heart, lung and blood diseases. In addition, we will develop standardized tables that would report each component of these calculations for an RCT to improve transparency and communication of the results. Using these methods, one can estimate the value of a perfect study that would eliminate all uncertainty and be translated immediately. Such an estimate would provide an upper bound to the value of the RCT. Alternatively; one can estimate the value of an RCT with a proposed design that would partially eliminate uncertainty. In other applications, one can derive optimal sample sizes or compare alternative designs (e.g. adaptive versus traditional) for a proposed study. Such information and presentations of expected risk and value from different RCT investments can help NHLBI with a quantitative visualization of its investment portfolio and optimize that portfolio over time.

 描述（由申请人提供）：NHLBI在确定如何最好地分配随机临床试验（RCT）投资方面面临重大挑战。目前，没有一致的 评估和比较NHLBI拟议RCT的机制，以最好地确定将有限资金投入何处。决策科学中的新方法可以提供有价值的信息，以加强NHLBI的RCT优先级排序过程。本项目的总体目标是开发一个实用信息价值（VOI）方法的综合工具包和相应的软件，供临床研究人员和资助者使用，以评估与心脏、肺和血液疾病相关的RCT的价值。此外，我们将制定标准化表格，报告RCT计算的每个组成部分，以提高结果的透明度和沟通。使用这些方法，人们可以估计一个完美的研究，将消除所有的不确定性，并立即翻译的价值。这样的估计将提供RCT值的上限。或者，人们可以估计一个RCT的价值与建议的设计，将部分消除不确定性。在其他应用中，可以为拟议的研究得出最佳样本量或比较替代设计（例如自适应与传统）。这些信息和来自不同RCT投资的预期风险和价值的介绍可以帮助NHLBI对其投资组合进行量化可视化，并随着时间的推移优化该投资组合。